Commentary
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update
Jacques Genest, Jiri Frohlich, George Fodor and Ruth McPherson
CMAJ October 28, 2003 169 (9) 921-924;
Jacques Genest
Jiri Frohlich
George Fodor
Article Figures & Tables
Tables
In this issue
Article tools
Respond to this article
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update
Jacques Genest, Jiri Frohlich, George Fodor, Ruth McPherson
CMAJ Oct 2003, 169 (9) 921-924;
Jump to section
Related Articles
Cited By...
- Evaluating the performance of a novel anthropometric index: weight adjusted for waist-to-height ratio (W-WHR) - for predicting cardiometabolic risk among adults in Addis Ababa
- Relationship between obstructive sleep apnoea syndrome and silent brain infarction
- Double-blind randomised controlled trial of the independent and synergistic effect of Spirulina maxima with exercise (ISESE) on general fitness, lipid profile and redox status in overweight and obese subjects: study protocol
- Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review
- Quality of Care for First Nations and Non-First Nations People with Diabetes
- Association of Apolipoprotein B and Nuclear Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 25 Clinical Studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices
- Inclusion of Stroke in Cardiovascular Risk Prediction Instruments: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
- Comprehensive Cardiac Rehabilitation for Secondary Prevention After Transient Ischemic Attack or Mild Stroke: I: Feasibility and Risk Factors
- A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study
- Cost Effectiveness and Screening Interval of Lipid Screening in Hodgkin's Lymphoma Survivors
- Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals
- Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
- Re-Evaluating Therapeutic Target Goals for Statin-Treated Patients: Time for Revolutionary Changes?
- Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
- Appropriateness of current thresholds for obesity-related measures among Aboriginal people
- One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk
- Are patients with hyperlipidemia undertreated?: Study of patients admitted to hospital with coronary events
- Do Women Have Worse Outcome After Stroke Caused by Intracranial Arterial Stenosis?
- Lignes directrices canadiennes de 2006 sur la prise en charge et la prevention de l'obesite chez les adultes et les enfants [sommaire]
- 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
- A comprehensive view of sex-specific issues related to cardiovascular disease
- The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin
- Risk Equation Determining Unsuccessful Cannulation Events and Failure to Maturation in Arteriovenous Fistulas (REDUCE FTM I)
- Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study
- Effect of Ezetimibe on the In Vivo Kinetics of ApoB-48 and ApoB-100 in Men With Primary Hypercholesterolemia
- Revisiting Rose: strategies for reducing coronary heart disease
- An evaluation of class effect
- Questioning the benefits of statins
- Questioning the benefits of statins
- Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia
- Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations
- Rebuttal
- The analysis by Manuel and colleagues creates controversy with headlines, not data
- The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed
- Comparison of the Associations of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study
- Dyslipidemia guidelines
- Dyslipidemia guidelines
- Dyslipidemia guidelines